Do I need a prescription for Vortioxetine 10mg tablets?

Vortioxetine 10mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Vortioxetine 10mg tablets?

Vortioxetine 10mg tablets is the generic name. It is available under brand names including: Brintellix 10mg tablets, Brintellix 10mg tablets, Brintellix 10mg tablets, Brintellix 10mg tablets, Brintellix 10mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Vortioxetine 10mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

10mg

Oral

Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD).

Active ingredients:

Vortioxetine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.03.04

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N06AX26

Check interactions for Vortioxetine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Vortioxetine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Vortioxetine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Vortioxetine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

5 branded products available

5 productsShow details

5 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Vortioxetine on the MHRA register

Brintellix 10mg tablets

Lundbeck Ltd

Brintellix 10mg tablets

CST Pharma Ltd

Brintellix 10mg tablets

Ethigen Ltd

Brintellix 10mg tablets

Mawdsley-Brooks & Company Ltd

Discontinued

Brintellix 10mg tablets

DE Pharmaceuticals

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£27.72indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

10 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Venlafaxine 37.5mg/5ml oral solution sugar free

Oral solution

37.5mg/5ml

Same therapeutic group

Venlafaxine 75mg/5ml oral solution sugar free

Oral solution

75mg/5ml

Same therapeutic group

Duloxetine 90mg gastro-resistant capsules

Capsule

90mg

Same therapeutic group

Duloxetine 120mg gastro-resistant capsules

Capsule

120mg

Same therapeutic group

Esketamine 28mg/0.2ml nasal spray unit dose

Spray

28mg/0.2ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Vortioxetine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(3)

Vortioxetine for treating major depressive episodes (TA367)

TA367

Technology appraisal

Updated Nov 2015

Esketamine nasal spray for treatment-resistant depression (TA854)

TA854

Technology appraisal

Updated Dec 2022

Depression in adults: treatment and management (NG222)

NG222

NICE guideline

Updated Jun 2022

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Vortioxetine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

30738611000001105

dm+d ID

30738611000001105

VTM (Virtual Therapeutic Moiety)

777946002

VMP (Virtual Medicinal Product)

30738611000001105

BNF code

04030400

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N06AX26

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

33 found

Half-life

66 hours

Mechanism

Vortioxetine is classified as a serotonin modulator and simulator (SMS) as it ha…

Food interactions

3 warnings

Human targets

7 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

7 to 11 hours

The maximal plasma vortioxetine concentration (Cmax) after dosing is reached within 7 to 11 hours postdose.…

Half-life

66 hours

Mean terminal halflife is approximately 66 hours

Protein binding

98%

The plasma protein binding of vortioxetine in humans is 98%, independent of plasma concentrations.…

Volume of distribution

2600 L

The apparent volume of distribution of vortioxetine is approximately 2600 L, indicating extensive extravascular distribution.

Metabolism

Vortioxetine is extensively metabolized primarily through oxidation via cytochrome P450 isozymes CYP2D6, CYP3A4/5, CYP2C19, CYP2C9, CYP2A6, CYP2C8…

Elimination

59%

Following a single oral dose of [14C]labeled vortioxetine, approximately 59% and 26% of the administered radioactivity was recovered in the urine and feces, respectively as metabolites.…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.

Properties:

solid

Avg. mass: 298.45 Da

View FDA drug label

DrugBank indication

Vortioxetine is indicated for the treatment of major depressive disorder (MDD).

Also known as(109)

Vortioxetina

Vortioxetine

Vortioxétine

vortioxetinum

5HT transporter

5HTT

HTT

SERT

Dosage forms(23)

Solution / drops (Oral) — 20 MG/ML

Tablet (Oral) — 20 mg/ml

Tablet (Oral) — 6.355 mg

Tablet, coated (Oral) — 5 mg

Tablet, film coated (Oral)

Tablet, film coated (Oral) — 10.00 mg

Tablet, film coated (Oral) — 20.00 mg

Tablet, film coated (Oral) — 5.00 mg

Molecular properties(18)

Drug interactions(1982)

Known interactions with other medications. Always consult a healthcare professional.

Ramipril

Moderate

DB00178

Vortioxetine may decrease the antihypertensive activities of Ramipril.

Check this interaction

Remikiren

Moderate

DB00212

Vortioxetine may decrease the antihypertensive activities of Remikiren.

Check this interaction

Guanadrel

Moderate

DB00226

Vortioxetine may decrease the antihypertensive activities of Guanadrel.

Check this interaction

Olmesartan

Moderate

DB00275

Vortioxetine may decrease the antihypertensive activities of Olmesartan.

Check this interaction

Minoxidil

Moderate

DB00350

Vortioxetine may decrease the antihypertensive activities of Minoxidil.

Check this interaction

Prazosin

Moderate

DB00457

Vortioxetine may decrease the antihypertensive activities of Prazosin.

Check this interaction

Trandolapril

Moderate

DB00519

Vortioxetine may decrease the antihypertensive activities of Trandolapril.

Check this interaction

Benazepril

Moderate

DB00542

Vortioxetine may decrease the antihypertensive activities of Benazepril.

Check this interaction

Candoxatril

Moderate

DB00616

Vortioxetine may decrease the antihypertensive activities of Candoxatril.

Check this interaction

Moexipril

Moderate

DB00691

Vortioxetine may decrease the antihypertensive activities of Moexipril.

Check this interaction

Nitroglycerin

Moderate

DB00727

Vortioxetine may decrease the antihypertensive activities of Nitroglycerin.

Check this interaction

Cryptenamine

Moderate

DB00785

Vortioxetine may decrease the antihypertensive activities of Cryptenamine.

Check this interaction

Eprosartan

Moderate

DB00876

Vortioxetine may decrease the antihypertensive activities of Eprosartan.

Check this interaction

Quinapril

Moderate

DB00881

Vortioxetine may decrease the antihypertensive activities of Quinapril.

Check this interaction

Deserpidine

Moderate

DB01089

Vortioxetine may decrease the antihypertensive activities of Deserpidine.

Check this interaction

Pentolinium

Moderate

DB01090

Vortioxetine may decrease the antihypertensive activities of Pentolinium.

Check this interaction

Trimethaphan

Moderate

DB01116

Vortioxetine may decrease the antihypertensive activities of Trimethaphan.

Check this interaction

Bretylium

Moderate

DB01158

Vortioxetine may decrease the antihypertensive activities of Bretylium.

Check this interaction

Terazosin

Moderate

DB01162

Vortioxetine may decrease the antihypertensive activities of Terazosin.

Check this interaction

Cilazapril

Moderate

DB01340

Vortioxetine may decrease the antihypertensive activities of Cilazapril.

Check this interaction

Saprisartan

Moderate

DB01347

Vortioxetine may decrease the antihypertensive activities of Saprisartan.

Check this interaction

Spirapril

Moderate

DB01348

Vortioxetine may decrease the antihypertensive activities of Spirapril.

Check this interaction

Dexpropranolol

Moderate

DB03322

Vortioxetine may decrease the antihypertensive activities of Dexpropranolol.

Check this interaction

Diethylnorspermine

Moderate

DB06445

Vortioxetine may decrease the antihypertensive activities of Diethylnorspermine.

Check this interaction

Temocapril

Moderate

DB08836

Vortioxetine may decrease the antihypertensive activities of Temocapril.

Check this interaction

Trimazosin

Moderate

DB09206

Vortioxetine may decrease the antihypertensive activities of Trimazosin.

Check this interaction

Rauwolfia serpentina root

Moderate

DB09363

Vortioxetine may decrease the antihypertensive activities of Rauwolfia serpentina root.

Check this interaction

Angiotensin 1-7

Moderate

DB11720

Vortioxetine may decrease the antihypertensive activities of Angiotensin 1-7.

Check this interaction

Imidapril

Moderate

DB11783

Vortioxetine may decrease the antihypertensive activities of Imidapril.

Check this interaction

BQ-123

Moderate

DB12054

Vortioxetine may decrease the antihypertensive activities of BQ-123.

Check this interaction

Dihydralazine

Moderate

DB12945

Vortioxetine may decrease the antihypertensive activities of Dihydralazine.

Check this interaction

Zofenopril

Moderate

DB13166

Vortioxetine may decrease the antihypertensive activities of Zofenopril.

Check this interaction

Guanoxan

Moderate

DB13211

Vortioxetine may decrease the antihypertensive activities of Guanoxan.

Check this interaction

Delapril

Moderate

DB13312

Vortioxetine may decrease the antihypertensive activities of Delapril.

Check this interaction

Vincamine

Moderate

DB13374

Vortioxetine may decrease the antihypertensive activities of Vincamine.

Check this interaction

Guanoxabenz

Moderate

DB13410

Vortioxetine may decrease the antihypertensive activities of Guanoxabenz.

Check this interaction

Tolonidine

Moderate

DB13429

Vortioxetine may decrease the antihypertensive activities of Tolonidine.

Check this interaction

Endralazine

Moderate

DB13435

Vortioxetine may decrease the antihypertensive activities of Endralazine.

Check this interaction

Cadralazine

Moderate

DB13452

Vortioxetine may decrease the antihypertensive activities of Cadralazine.

Check this interaction

Bietaserpine

Moderate

DB13575

Vortioxetine may decrease the antihypertensive activities of Bietaserpine.

Check this interaction

Guanazodine

Moderate

DB13604

Vortioxetine may decrease the antihypertensive activities of Guanazodine.

Check this interaction

Methoserpidine

Moderate

DB13631

Vortioxetine may decrease the antihypertensive activities of Methoserpidine.

Check this interaction

Guanoclor

Moderate

DB13779

Vortioxetine may decrease the antihypertensive activities of Guanoclor.

Check this interaction

Tocopherylquinone

Moderate

DB14094

Vortioxetine may decrease the antihypertensive activities of Tocopherylquinone.

Check this interaction

Benazeprilat

Moderate

DB14125

Vortioxetine may decrease the antihypertensive activities of Benazeprilat.

Check this interaction

Fosinoprilat

Moderate

DB14207

Vortioxetine may decrease the antihypertensive activities of Fosinoprilat.

Check this interaction

Ramiprilat

Moderate

DB14208

Vortioxetine may decrease the antihypertensive activities of Ramiprilat.

Check this interaction

Perindoprilat

Moderate

DB14213

Vortioxetine may decrease the antihypertensive activities of Perindoprilat.

Check this interaction

Quinaprilat

Moderate

DB14217

Vortioxetine may decrease the antihypertensive activities of Quinaprilat.

Check this interaction

Enalapril

Moderate

DB00584

Vortioxetine may decrease the antihypertensive activities of Enalapril.

Check this interaction

Showing 50 of 1982 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol.

Advice

Avoid St. John's Wort. When administered with vortioxetine, this herb may increase the risk of serotonin syndrome.

Advice

Take with or without food.

Toxicity & overdose

The most commonly reported adverse effects during clinical trials were nausea, diarrhea, and dry mouth. The FDA label includes a blackbox warning for the following risks and complications: serotonin syndrome, especially when combined with other serotonergic agents; increased risk of abnormal bleeding, especially when combined with NSAIDs, aspirin, or other drugs that affect coagulation; activation of mania/hypomania; hyponatremia; and suicidal thoughts and behaviour in children, adolescents, and young adults.

How it works

Mechanism of action

Vortioxetine is classified as a serotonin modulator and simulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, while also acting as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors.

Pharmacodynamics

Vortioxetine binds with high affinity to the human serotonin transporter (Ki=1.6 nM), but not to the norepinephrine (Ki=113 nM) or dopamine (Ki>1000 nM) transporters. Vortioxetine potently and selectively inhibits reuptake of serotonin by inhibition of the serotonin transporter (IC50=5.4 nM). Specifically, vortioxetine binds to 5HT3 (Ki=3.7 nM), 5HT1A (Ki=15 nM), 5HT7 (Ki=19 nM), 5HT1D (Ki=54 nM), and 5HT1B (Ki=33 nM), receptors and is a 5HT3, 5HT1D, and 5HT7 receptor antagonist, 5HT1B receptor partial agonist, and 5HT1A receptor agonist.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

The maximal plasma vortioxetine concentration (Cmax) after dosing is reached within 7 to 11 hours postdose. Absolute bioavailability is 75%. No effect of food on the pharmacokinetics was observed.

Half-life

Mean terminal halflife is approximately 66 hours

Protein binding

The plasma protein binding of vortioxetine in humans is 98%, independent of plasma concentrations. No apparent difference in the plasma protein binding between healthy subjects and subjects with hepatic (mild, moderate) or renal (mild, moderate, severe, ESRD) impairment is observed.

Volume of distribution

The apparent volume of distribution of vortioxetine is approximately 2600 L, indicating extensive extravascular distribution.

Metabolism

Vortioxetine is extensively metabolized primarily through oxidation via cytochrome P450 isozymes CYP2D6, CYP3A4/5, CYP2C19, CYP2C9, CYP2A6, CYP2C8 and CYP2B6 and subsequent glucuronic acid conjugation. CYP2D6 is the primary enzyme catalyzing the metabolism of vortioxetine to its major, pharmacologically inactive, carboxylic acid metabolite, and poor metabolizers of CYP2D6 have approximately twice the vortioxetine plasma concentration of extensive metabolizers.

Route of elimination

Following a single oral dose of [14C]labeled vortioxetine, approximately 59% and 26% of the administered radioactivity was recovered in the urine and feces, respectively as metabolites. Negligible amounts of unchanged vortioxetine were excreted in the urine up to 48 hours.

Drug targets(7)

Proteins and enzymes this drug interacts with in the body

Sodium-dependent serotonin transporter

BE0000749

SLC6A4

inhibitor

Specific functionactin filament binding

Cellular location

Cell membrane

General function & pharmacology

Serotonin transporter that cotransports serotonin with one Na(+) ion in exchange for one K(+) ion and possibly one proton in an overall electroneutral transport cycle. Transports serotonin across the plasma membrane from the extracellular compartment to the cytosol thus limiting serotonin intercellular signaling .
PMID:10407194 PMID:12869649 PMID:21730057 PMID:27049939 PMID:27756841 PMID:34851672

Essential for serotonin homeostasis in the central nervous system. In the developing somatosensory cortex, acts in glutamatergic neurons to control serotonin uptake and its trophic functions accounting for proper spatial organization of cortical neurons and elaboration of sensory circuits.

In the mature cortex, acts primarily in brainstem raphe neurons to mediate serotonin uptake from the synaptic cleft back into the pre-synaptic terminal thus terminating serotonin signaling at the synapse (By similarity). Modulates mucosal serotonin levels in the gastrointestinal tract through uptake and clearance of serotonin in enterocytes. Required for enteric neurogenesis and gastrointestinal reflexes (By similarity).

Regulates blood serotonin levels by ensuring rapid high affinity uptake of serotonin from plasma to platelets, where it is further stored in dense granules via vesicular monoamine transporters and then released upon stimulation .
PMID:17506858 PMID:18317590
Mechanistically, the transport cycle starts with an outward-open conformation having Na1(+) and Cl(-) sites occupied. The binding of a second extracellular Na2(+) ion and serotonin substrate leads to structural changes to outward-occluded to inward-occluded to inward-open, where the Na2(+) ion and serotonin are released into the cytosol. Binding of intracellular K(+) ion induces conformational transitions to inward-occluded to outward-open and completes the cycle by releasing K(+) possibly together with a proton bound to Asp-98 into the extracellular compartment.

Na1(+) and Cl(-) ions remain bound throughout the transport cycle .
PMID:10407194 PMID:12869649 PMID:21730057 PMID:27049939 PMID:27756841 PMID:34851672

Additionally, displays serotonin-induced channel-like conductance for monovalent cations, mainly Na(+) ions. The channel activity is uncoupled from the transport cycle and may contribute to the membrane resting potential or excitability (By similarity)

5-hydroxytryptamine receptor 3A

BE0000311

HTR3A

antagonist

Specific functionexcitatory extracellular ligand-gated monoatomic ion channel activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons

5-hydroxytryptamine receptor 7

BE0000650

HTR7

antagonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen .
PMID:35714614 PMID:8226867
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:35714614 PMID:8226867
HTR7 is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity PMID:35714614

5-hydroxytryptamine receptor 1B

BE0000797

HTR1B

partial agonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:10452531 PMID:1315531 PMID:1328844 PMID:1348246 PMID:1351684 PMID:1559993 PMID:1565658 PMID:1610347 PMID:23519210 PMID:23519215 PMID:29925951 PMID:8218242

Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD) .
PMID:23519210 PMID:23519215 PMID:29925951

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:10452531 PMID:1315531 PMID:1328844 PMID:1348246 PMID:1351684 PMID:1559993 PMID:1565658 PMID:1610347 PMID:23519210 PMID:23519215 PMID:29925951 PMID:8218242

HTR1B is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission by inhibiting adenylate cyclase activity .
PMID:29925951 PMID:35610220
Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:29925951
Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior .
PMID:18476671 PMID:20945968
Besides, plays a role in vasoconstriction of cerebral arteries PMID:15853772

5-hydroxytryptamine receptor 1A

BE0000291

HTR1A

agonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:37935376 PMID:37935377 PMID:8138923 PMID:8393041

Also functions as a receptor for various drugs and psychoactive substances .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:38552625 PMID:8138923 PMID:8393041

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:22957663 PMID:3138543 PMID:33762731 PMID:8138923 PMID:8393041

HTR1A is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission: signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores .
PMID:33762731 PMID:35610220
Beta-arrestin family members regulate signaling by mediating both receptor desensitization and resensitization processes .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior .
PMID:18476671 PMID:20363322 PMID:20945968

Plays a role in the response to anxiogenic stimuli PMID:18476671 PMID:20363322 PMID:20945968

Metabolizing enzymes(8)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2D6Cytochrome P450 2D6

substrate

CYP3A4Cytochrome P450 3A4

substrate

CYP3A5Cytochrome P450 3A5

substrate

CYP2C19Cytochrome P450 2C19

substrate

CYP2C9Cytochrome P450 2C9

substrate

CYP2A6Cytochrome P450 2A6

substrate

CYP2C8Cytochrome P450 2C8

substrate

CYP2B6Cytochrome P450 2B6

substrate

Scientific references(4)

Bang-Andersen B., Ruhland T., Jorgensen M., Smith G., Frederiksen K., Jensen K.G., Zhong H., Nielsen S.M., Hogg S., Mork A., Stensbol T.B.

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

Journal of Medicinal Chemistry

2011 May 1254(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12

PMID: 21486038 DOI: 10.1021/jm101459g

Stenkrona P., Halldin C., Lundberg J.

5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004).

A PET study in control subjects

Eur Neuropsychopharmacol. 2013 Oct23(10):1190-8. doi: 10.1016/j.euroneuro.2013.01.002. Epub 2013 Feb 18

PMID: 23428337 DOI: 10.1016/j.euroneuro.2013.01.002

Mork A., Montezinho L.P., Miller S., Trippodi-Murphy C., Plath N., Li Y., Gulinello M., Sanchez C.

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

Pharmacology Biochemistry Behav

2013 Apr105:41-50. doi: 10.1016/j.pbb.2013.01.019. Epub 2013 Feb 1

PMID: 23380522 DOI: 10.1016/j.pbb.2013.01.019

Hvenegaard M.G., Bang-Andersen B., Pedersen H., Jorgensen M., Puschl A., Dalgaard L.

Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004.

Drug Metabolism and Disposition

2012 Jul40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11

PMID: 22496396 DOI: 10.1124/dmd.112.044610

ATC classification(1 code)

ATC N06AX26

Salt forms(2)

Vortioxetine hemihydrobromide(DBSALT003590)

Vortioxetine hydrobromide(DBSALT001117)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(3)

8aw2

8bla

8blb

Commercial products(63)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Vortioxetine

DB09068

CAS number

508233-74-7

UNII (FDA)

3O2K1S3WQV

InChI Key (molecular fingerprint)

YQNWZWMKLDQSAC-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

22527

ChEBI

76016

PubChem Compound

71768094

PubChem Substance

310265001

KEGG Drug

D10184

ChemSpider

8141643

BindingDB

50400902

PharmGKB

PA166122595

PDB

VTX

Wikipedia

Vortioxetine

ChEMBL

CHEMBL2104993

ZINC

ZINC000034051848

RxCUI

1455099

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11050

GenAtlas

SLC6A4

GeneCards

SLC6A4

GenBank Gene Database

X70697

GenBank Protein Database

36433

Guide to Pharmacology

928

UniProtKB

P31645

UniProt Accession

SC6A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5297

GenAtlas

HTR3A

GeneCards

HTR3A

GenBank Gene Database

D49394

GenBank Protein Database

681914

IUPHAR

373

Guide to Pharmacology

373

UniProtKB

P46098

UniProt Accession

5HT3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5302

GenAtlas

HTR7

GeneCards

HTR7

GenBank Gene Database

U68487

GenBank Protein Database

1857143

IUPHAR

Guide to Pharmacology

UniProtKB

P34969

UniProt Accession

5HT7R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5287

GenAtlas

HTR1B

GeneCards

HTR1B

GenBank Gene Database

D10995

GenBank Protein Database

219679

IUPHAR

Guide to Pharmacology

UniProtKB

P28222

UniProt Accession

5HT1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:285

GenAtlas

ADRB1

GeneCards

ADRB1

GenBank Gene Database

J03019

GenBank Protein Database

178200

IUPHAR

Guide to Pharmacology

UniProtKB

P08588

UniProt Accession

ADRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11048

GenAtlas

SLC6A2

GeneCards

SLC6A2

GenBank Gene Database

M65105

GenBank Protein Database

189258

Guide to Pharmacology

926

UniProtKB

P23975

UniProt Accession

SC6A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2638

GenAtlas

CYP3A5

GeneCards

CYP3A5

GenBank Gene Database

J04813

GenBank Protein Database

181346

Guide to Pharmacology

1338

UniProtKB

P20815

UniProt Accession

CP3A5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2610

GenAtlas

CYP2A6

GeneCards

CYP2A6

GenBank Gene Database

X13897

Guide to Pharmacology

1321

UniProtKB

P11509

UniProt Accession

CP2A6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2622

GenAtlas

CYP2C8

GeneCards

CYP2C8

GenBank Gene Database

M17397

Guide to Pharmacology

1325

UniProtKB

P10632

UniProt Accession

CP2C8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

Patent information

10 active patents, 1 expired

9278096

United States

Paediatric ext.

Approved 8 Mar 2016 · Expires 21 Sept 2032

6y 5m

8722684

United States

Paediatric ext.

Approved 13 May 2014 · Expires 30 Dec 2031

5y 9m

8969355

United States

Paediatric ext.

Approved 3 Mar 2015 · Expires 15 Dec 2027

1y 8m

9227946

United States

Paediatric ext.

Approved 5 Jan 2016 · Expires 15 Dec 2027

1y 8m

9861630

United States

Paediatric ext.

Approved 9 Jan 2018 · Expires 15 Dec 2027

1y 8m

The earliest active patent expires December 2026. Generic versions may become available after this date.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated about 1 month ago(4 Mar 2026)

Back to medicines

Vortioxetine 10mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(3)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
15

Chemical identifiers

Vortioxetine

Additional database identifiers

Patent information

DrugBank citations

Vortioxetine 10mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(3)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science15

Chemical identifiers

Vortioxetine

Additional database identifiers

Patent information

DrugBank citations

Deep science
15